Search Results

Coya Therapeutics, Inc. announces the expansion of its research collaboration with the Houston Methodist Research Institute (“HMRI”) through a sponsored research agreement (SRA) covering multiple initiatives.

While Houston isn’t yet on the same level as major life sciences hubs, it has plenty to offer and room to grow, according to CNS Pharmaceuticals, RadioMedix and Greater Houston Partnership executives.

Health Data Analytics Institute announced a joint presentation next week with Houston Methodist on how they are “Deploying Clinical AI at Scale,” a key advance in unleashing a long-awaited data-driven transformation in medical care.

U.S. Army Institute of Surgical Research to conduct key studies intended to further our knowledge of the effects of Claromer technology

SOLASCURE Ltd, a biotechnology company developing a novel treatment to transform chronic wound care, announced it has been selected for Innovate UK’s Global Incubator Programme in Houston, US.

The Association for the Advancement of Blood & Biotherapies (AABB) is pleased to announce the return of the Biotherapies Pavilion at the 2024 AABB Annual Meeting, which will take place Oct. 19-22 in Houston, Texas.

Coya Therapeutics, Inc. announces the presentation of data demonstrating the role of the peripheral immune system in the pathophysiology of Frontotemporal Dementia (FTD) from a biomarker study conducted at the Houston Methodist Hospital by Dr. Stanley Appel and Dr. Alireza Faridar and funded by the Houston Methodist Clinical Scholar Award Program.

Renal Research Institute, a global leader in dialysis and nephrology research and a subsidiary of Fresenius Medical Care AG, announced together with the Karolinska Institutet a joint symposium, “Prevention of CKD progression: the impact of new therapeutics.” The Karolinska Institutet is one of the world’s leading medical universities.